|
KMID : 0371319940460040502
|
|
Journal of the Korean Surgical Society
1994 Volume.46 No. 4 p.502 ~ p.510
|
|
|
A Study of EGFR, ras Oncogene Product and p53 as a Prognostic Factor in Patients with Gastric Carcinoma
|
|
민진식
이희대/이기범/최승호/박찬일/노성훈
|
|
|
Abstract
|
|
|
There are several evidences that cancer arise as the result of multiple alterations of gene, and many attempts were made recently to understand the role of oncogene, growth factor and its receptor, and suppressor gene as a prognostic indicator.
To determine whether alteration in EGFR, ras oncogene product and p53 are associated with prognosis in gastric carcinoma, the analysis was performed on paraffin embedded tissues of 119 primary gastric carcinomas by an immunohistochemical assay
using
LSAB(labelled streptavidin biotin) method. EGFR was positive in 53 cases(44.5%), ras oncogene product in 21 (17.6%), and p53 in 39(32.8%). The 5-year survival rate was 57.8% in EGFR positive and 71.3% in EGFR negative, especially of the patients
with
serosal invasion, 44.2% in EGFR positive and 69.6% in EGFR negative(p<0.05). Ras oncogene product positive and negative had 5 years survival rate of 47.9% and 69.0% in each, and in each, and in stage II, the survival difference was more distint.
The
5-year survival rat in p53 positive and p53 negative were 56.7% and 68.9% respectively(p<0.05). In patients with stage II or without serosal invasion, there was slightly survival difference between p53 negative.
So we concluded that EGFR and ras oncogene expression are significantly associated with worse prognosis in gastric carcinomas, especially in case of serosal invasion or stage III. although there was no significant difference in survival rate
according
to p53, we suggested that p53 may be prognostic indicator in patients with stage II or no serosal invasion.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|